The Oklahoma City Innovation District will soon welcome a “once-in-a-generation” biomanufacturing workforce training center (BWTC) program to benefit all Oklahomans. One of the only programs of its kind within the United States, the BWTC program presents inclusive, non-degreed careers within the city’s emerging bioscience industry.
Greater Oklahoma City Chamber Executive Vice President Jeff Seymour was in Washington, D.C., this morning attending an invitation-only biotechnology summit at the White House. The event launched a new initiative designed to ensure America’s place in the world of biotechnology and biomanufacturing.
President Biden announced the Oklahoma Biotech Innovation Cluster as one of 21 winners of the $1 billion Build Back Better Regional Challenge, the most impactful regional economic development competition in decades.
The Chamber’s Economic Development staff is on a constant mission to grow existing industries, recruit new companies and develop an active entrepreneurial environment, with the goal of creating quality jobs and a diverse economy for the region; in other words, bring new investment to the city.
The San Diego Convention Center was booming with wall-to-wall activity last month as thousands of bioscience professionals converged for the 2022 Biotechnology Innovation Organization International Convention (BIO). Among them was a large contingent from Oklahoma who joined forces as part of the Oklahoma Biosciences Association (OKBio) exhibitor booth.
Chamber members, Oklahoma Health Sciences Center (OUHSC) and Oklahoma Medical Research Foundation (OMRF), were granted $5.5 million from Presbyterian Health Foundation (PHF) for medical research.
Learn more about all the progress happening with Convergence and the OKC Innovation District during the Chamber's July Forum at Vast July 20.
OU Health Stephenson Cancer Center has announced a historic first for the campus and the state: A new cancer drug, called OK-1, which was conceived and created by an OU College of Medicine researcher and developed entirely in Oklahoma, without the support of a pharmaceutical company, is being tested in humans for the first time in a Phase 1 clinical trial.
